-
Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment
•
US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin’s founder Dr. Eugene Chen…
